Minerva Neurosciences (NERV) Other Non Operating Income (2013 - 2026)
Minerva Neurosciences posted quarterly Other Non Operating Income of -$1804.0 for Q1 2026, up 78.46% year-on-year from -$1010.9 in Q1 2025, and up 91.34% on a QoQ basis from -$20823.0 in Q4 2025.
Minerva Neurosciences (NERV) has 14 years of Other Non Operating Income data on file, last reported at -$1804.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non Operating Income rose 78.46% year-over-year to -$1804.0; the trailing twelve-month figure through Mar 2026 stood at -$49983.0 (down 216.45% YoY), and the FY2025 full-year result was -$56555.0, down 2836.4% from the prior year.
- Other Non Operating Income for Q1 2026 stood at -$1804.0, up from -$20823.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $10383.0 in Q4 2024 and bottomed at -$27606.0 in Q4 2022.
- The 5-year median for Other Non Operating Income is -$6246.0 (2025), against an average of -$7544.8.
- The widest annual swing landed in 2022, when Other Non Operating Income tumbled 567.13%; it then jumped 163.24% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at -$27606.0 in 2022, then soared by 30.28% to -$19247.0 in 2023, then surged by 153.95% to $10383.0 in 2024, then plunged by 300.55% to -$20823.0 in 2025, then soared by 91.34% to -$1804.0 in 2026.
- The last three Other Non Operating Income figures came in at -$1804.0 (Q1 2026), -$20823.0 (Q4 2025), and -$6246.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,804.00 |
| Dec 31, 2025 | -20,823.00 |
| Sep 30, 2025 | -6,246.00 |
| Jun 30, 2025 | -21,110.00 |
| Mar 31, 2025 | -8,376.00 |
| Dec 31, 2024 | 10,383.00 |
| Sep 30, 2024 | -13,108.00 |
| Jun 30, 2024 | -4,694.00 |
| Mar 31, 2024 | 5,493.00 |
| Dec 31, 2023 | -19,247.00 |
| Sep 30, 2023 | -5,096.00 |
| Jun 30, 2023 | -7,206.00 |
| Mar 31, 2023 | -8,686.00 |
| Dec 31, 2022 | -27,606.00 |
| Sep 30, 2022 | 2,063.00 |
| Jun 30, 2022 | 1,596.00 |
| Mar 31, 2022 | -3,794.00 |
| Dec 31, 2021 | -4,138.00 |
| Sep 30, 2021 | -4,855.00 |
| Jun 30, 2021 | -18,997.00 |
| Mar 31, 2021 | -4,856.00 |
| Dec 31, 2020 | -26,634.00 |
| Sep 30, 2020 | -27,496.00 |
| Jun 30, 2020 | -3,661.00 |
| Mar 31, 2020 | -9,392.00 |
| Dec 31, 2019 | -10,748.00 |
| Sep 30, 2019 | -4,766.00 |
| Jun 30, 2019 | -6,718.00 |
| Mar 31, 2019 | -6,313.00 |
| Dec 31, 2018 | -5,025.00 |
| Sep 30, 2018 | -10,987.00 |
| Jun 30, 2018 | 29,274.00 |
| Mar 31, 2018 | -18,109.00 |
| Dec 31, 2017 | -10,672.00 |
| Sep 30, 2017 | -9,417.00 |
| Jun 30, 2017 | -20,115.00 |
| Mar 31, 2017 | -16,683.00 |
| Dec 31, 2016 | 4,157.00 |
| Sep 30, 2016 | -2,578.00 |
| Jun 30, 2016 | -15,462.00 |
| Mar 31, 2016 | -9,512.00 |
| Dec 31, 2015 | -421.00 |
| Sep 30, 2015 | -2,280.00 |
| Jun 30, 2015 | -29,112.00 |
| Mar 31, 2015 | 15,960.00 |
| Dec 31, 2014 | 3,752.00 |
| Sep 30, 2014 | 10,989.00 |
| Jun 30, 2014 | 10,549.00 |
| Mar 31, 2014 | -6,562.00 |
| Dec 31, 2013 | -26,090.00 |
| Sep 30, 2013 | -2,887.00 |